PubMed=2578514; DOI=10.4049/jimmunol.134.3.1623
Yodoi J., Teshigawara K., Nikaido T., Fukui K., Noma T., Honjo T., Takigawa M., Sasaki M.S., Minato N., Tsudo M., Uchiyama T., Maeda M.
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).
J. Immunol. 134:1623-1630(1985)

PubMed=3098894; DOI=10.1084/jem.165.1.223
Teshigawara K., Wang H.-M., Kato K., Smith K.A.
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.
J. Exp. Med. 165:223-238(1987)

PubMed=1313126
Yoneda N., Tatsumi E., Kawano S., Teshigawara K., Oka T., Fukuda M., Yamaguchi N.
Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT.
Leukemia 6:136-141(1992)

PubMed=9787181; DOI=10.1182/blood.V92.9.3410
Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.
PTEN gene alterations in lymphoid neoplasms.
Blood 92:3410-3415(1998)

PubMed=10803505; DOI=10.1038/sj.leu.2401778
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Leukemia 14:777-782(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x
Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.
Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Cancer Sci. 97:605-610(2006)

PubMed=19194464; DOI=10.1038/leu.2009.3
Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H., Klinkebiel D.L., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K., Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Leukemia 23:1139-1151(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255
Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G., Greiner T.C., Kucuk C., Deffenbacher K., Vose J.M., Smith L., Au W.Y., Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H., Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Leukemia 25:348-358(2011)

PubMed=25586472; DOI=10.1038/ncomms7025
Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A., Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K., de Leval L., McKeithan T.W., Chan W.C.
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
Nat. Commun. 6:6025.1-6025.12(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)